Abstract:Six novel mononuclear Schiff base metal complexes of the type [ML 1 L 2 ]X and [ML 1 L 2 X], where M D Cu(II), Ni(II), Co(II), Mn(II), Zn(II), and VO(IV) have been synthesized by condensation of 1-(1-(pyridine-2-yl)ethylidene)thiosemicarbazide (L 1 ) and 1-(1-(2,4-dihydroxyphenyl)ethylidene)thiosemicarbazide (L 2 ) in the presence of divalent metal salts. The synthesized ligands and complexes were structurally characterized on the basis of elemental analysis, IR, UV-visible, 1 H NMR spectroscopy, molar conduct… Show more
“…This may be due to a decrease in hydrogen bonding of -OH groups in C 62 (compared to free ligands) with group of the enzymes of microbes which inhibit the penitration of C 62 to the cell walls. [128] It has been reported that often the activity of a biologically active ligand decreases or completely vanishes after replacement of phenolic protons by a metal ion since the activity of a particular molecule may be due to that phenolic group. [67] An other interesting complex C 63 having molecular structure and coordiantion behaviour similar to C 59 was synthesized using guaifenesin ( a L 63 ) and 2aminoacetic acid ( b L 63 ).…”
Section: Mn-complexes With Mixed Ligandsmentioning
confidence: 99%
“…C 62 proved to have lower activity compared to ligands against almost all the tested microbes (Table ). This may be due to a decrease in hydrogen bonding of ‐OH groups in C 62 (compared to free ligands) with group of the enzymes of microbes which inhibit the penitration of C 62 to the cell walls . It has been reported that often the activity of a biologically active ligand decreases or completely vanishes after replacement of phenolic protons by a metal ion since the activity of a particular molecule may be due to that phenolic group .…”
Section: Mn–complexes With Mixed Ligandsmentioning
The clinical success of metallodrugs is rapidly increasing. The historical use of cisplatin and recently a successful marketing of its clinically advanced derivatives (oxaliplatin, carboplatin, nedaplatin, lobaplatin and heptaplatin) for the treatment of various types of cancer has opened new horizons for metal based drugs. Complexes of cobalt, gold, ruthenium, palladium, manganese and even arsenic are either being marketed or close to get success in clinical trials for the treatment of various diseases. Current review compiles the advances on manganese complexes and their biomedical applications. A possible structure activity relationship has been discussed.
“…This may be due to a decrease in hydrogen bonding of -OH groups in C 62 (compared to free ligands) with group of the enzymes of microbes which inhibit the penitration of C 62 to the cell walls. [128] It has been reported that often the activity of a biologically active ligand decreases or completely vanishes after replacement of phenolic protons by a metal ion since the activity of a particular molecule may be due to that phenolic group. [67] An other interesting complex C 63 having molecular structure and coordiantion behaviour similar to C 59 was synthesized using guaifenesin ( a L 63 ) and 2aminoacetic acid ( b L 63 ).…”
Section: Mn-complexes With Mixed Ligandsmentioning
confidence: 99%
“…C 62 proved to have lower activity compared to ligands against almost all the tested microbes (Table ). This may be due to a decrease in hydrogen bonding of ‐OH groups in C 62 (compared to free ligands) with group of the enzymes of microbes which inhibit the penitration of C 62 to the cell walls . It has been reported that often the activity of a biologically active ligand decreases or completely vanishes after replacement of phenolic protons by a metal ion since the activity of a particular molecule may be due to that phenolic group .…”
Section: Mn–complexes With Mixed Ligandsmentioning
The clinical success of metallodrugs is rapidly increasing. The historical use of cisplatin and recently a successful marketing of its clinically advanced derivatives (oxaliplatin, carboplatin, nedaplatin, lobaplatin and heptaplatin) for the treatment of various types of cancer has opened new horizons for metal based drugs. Complexes of cobalt, gold, ruthenium, palladium, manganese and even arsenic are either being marketed or close to get success in clinical trials for the treatment of various diseases. Current review compiles the advances on manganese complexes and their biomedical applications. A possible structure activity relationship has been discussed.
“…On the other hand, the biological activities of metal complexes have gained attention during the last two decades due to their diverse biomedical applications like antibacterial (Osman et al, 2012;Sakthilatha et al, 2015;Wakil et al, 2017), antifungal (Ran et al, 2011El-Tabl et al, 2012), cytotoxicity El-Seidy et al, 2013), antitumor (Chang et al, 2015;Rubino et al, 2016), antiviral (Abou-Melha et al, 2015, DNA cleavage (Kokare et al, 2017;Subbaraj et al, 2014), antimalarial (Hubin et al, 2014, antioxidant (Abdel-Monem et al, 2017;Lakshmi et al, 2011), analgesic and anti-inflammatory (Hoonur et al, 2010; activities. Cisplatin (6), cis-[PtCl 2 (NH 3 ) 2 ], is the most famous and the best-known example of a small molecule-metal complex that has been used in the chemotherapy for various cancer diseases (Ott and Gust, 2007).…”
Bioorganometallic chemistry was devoted to the synthesis of new organometallic compounds and their biological and medicinal activities. Ferrocenyl complexes display various pharmacological intеrests such as antibacterial and antifungal activities. This review article will focus on antimicrobial activities of ferrocenyl complexes (Cu, Co, Ni, and Zn).
The 2,4,6‐tris(2‐pyridyl)‐1,3,5‐triazine (tptz) undergoes hydrolysis in the presence of VO(SO4) in an alkaline solution, affording mainly the bis(2‐pyridyl carbonyl)amid) VO2 complex, designated as [VO2(bpca)]. Single‐crystal X‐ray crystallography revealed that the coordination of V in complex is a distorted square‐pyramid coordinated with three nitrogen of bis(2‐pyridyl carbonyl)amid) ligand and two binding oxygen atoms. The prepared complex which successfully supported on modified Fe3O4 nanoparticles using tetraethylorthosilicate (TEOS) and (3‐aminopropyl)trimethoxysilane(APTMS)was designated as Fe3O4@SiO2@APTMS@[VO2(bpca)] complex (nanocatalyst). The complex and nanocatalyst were characterized by means of FT‐IR, XRD, VSM, SEM and TEM. The catalytic activity of [VO2(bpca)] complex and Fe3O4@SiO2@APTMS@complex as catalysts 1 and 2 were evaluated by the epoxidation of geraniol, 3‐methyl‐2‐buten‐1‐ol, trans‐2‐hexen‐1‐ol and 1‐octen‐3‐ol with 70–98% conversions and 95–100% selectivities. Based on the obtained results, the heterogeneity and reusability of the catalyst seems promising. In addition, the in vitro antibacterial activity of [VO2 (bpca)] complex have also been evaluated and compared to the activities of other vanadium complexes, tptz ligand and two standard antibacterial drugs, Nalidixic acid and Vancomycin.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.